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Aberrant immune activation is a strong correlate of HIV disease progression, but little is known about how immune
activation alters susceptibility to HIV infection. Susceptibility to HIV infection varies between individuals, but the
immunological determinants of HIV transmission are not well understood. Here, we present evidence from studies
of HIV transmission in the context of clinical trials and HIV-exposed seronegative (HESN) cohorts that implicates
elevated immune activation as a risk factor for acquiring HIV. We propose a model of protection from infection
based on a phenotype of low baseline immune activation referred to as immune quiescence. Immune quiescence is
evidenced by reduced expression of T cell activation markers, low levels of generalized gene transcription and low
levels of proinflammatory cytokine and chemokine production in the periphery and genital mucosa of HESN. Since
HIV preferentially replicates in activated CD4+ T cells, immune quiescence may protect against infection by limiting
HIV target cell availability. Although the determinants of immune quiescence are unclear, several potential factors
have been identified that may be involved in driving this phenotype. HESN were shown to have elevated
proportions of regulatory T cells (Tregs), which are known to suppress T cell activation. Likewise, proteins involved
in controlling inflammation in the genital tract have been found to be elevated in HESN. Furthermore, expression of
interferon regulatory factor 1 (IRF-1) is reduced in HESN as a consequence of genetic polymorphisms and
differential epigenetic regulation. Since IRF-1 is an important regulator of immune responses, it may play a role in
maintaining immune quiescence. Based on this model, we propose a novel avenue for HIV prevention targeted
based on reducing host mucosal immune activation.
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Despite the advances in the management of HIV infec-
tion, new HIV infections remain high. A combination
of proven prevention approaches and novel approaches
are needed to stem this tide. While it is known that im-
mune activation drives HIV disease progression, its role
in HIV susceptibility is unclear. In this review, we will
present evidence that immune activation is a key deter-
minant in viral transmission and propose a model of
immune quiescence (IQ) as a mechanism of protection
from infection. Reducing susceptibility to HIV infection
by inducing IQ represents a novel mechanism of HIV
prevention.* Correspondence: keith.fowke@med.umanitoba.ca
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HIV dependency on immune activation
HIV replication and immune activation are critically inter-
twined. Immune activation has been recognized as a sig-
nificant factor in the destruction of the immune response
and rapid HIV disease progression [1], but the relationship
between immune activation and susceptibility to HIV
infection is not well defined. In vitro studies demonstrated
that quiescent CD4+ T cells can be infected by HIV, but
viral replication is inefficient [2]. As such, HIV preferen-
tially establishes productive infection in activated T cells
[3,4]. One reason for this preference is the large number
of host factors required for efficient HIV replication [5-7],
which are primarily expressed in activated cells. Based on
these observations, it is reasonable to hypothesize that
individuals with lower levels of immune activation would
have lower susceptibility to HIV infection. Indeed, in
the Pumwani HESN cohort, reduced susceptibility ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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low levels of activated CD4+ CD69+ T cells and elevated
levels of immunosuppressive Tregs [8], in agreement
with earlier data showing elevated HIV susceptibility of
lymphocytes from individuals with high immune activa-
tion [9]. These data support a previous study, which
showed that unstimulated cells from HESN had reduced
susceptibility to infection compared to controls, but
levels of infection were comparable when cells were pre-
activated with a mitogen [10]. In addition to these
in vitro data, evidence gathered from various models
support this immune quiescence hypothesis, as detailed
in the sections below.
Models informing the role of immune activation in HIV
transmission
Microbicide trials
Functional studies conducted in conjunction with clinical
trials of microbicide candidates have been instrumental in
studying the determinants of HIV transmission. Early
microbicide candidates were not effective at preventing
acquisition, and some were unfortunately associated with
increased HIV transmission rates. For instance, the micro-
bicides cellulose sulfate and nonoxynol-9 disrupted tight
junctions between epithelial cells and caused inflammation
in the female genital tract (FGT), characterized by en-
hanced IL-1α and IL-8 expression and activation of the
NF-kB pathway [11-13]. It has been suggested that this in-
flammation resulted in more HIV target cells at the site of
viral exposure, thereby increasing the risk of HIV infection
[13]. The most promising microbicide candidate to date
was a 1% tenofovir gel, which demonstrated a 39%
protective effect when tested in the CAPRISA 004 trial
[14]. In that trial, the extent of immune activation prior to
exposure was correlated directly with increased risk of HIV
seroconversion, irrespective of microbicide or placebo use
[15]. Systemic immune activation was marked by activation
of natural killer (NK) cells, elevated levels of plasma
cytokines and elevated levels of CD8+ T cell degranulation
relative to women who remained HIV negative [15]. The
authors of this study concluded that suppression of innate
immune activation should be considered when developing
the next generation of antiretroviral microbicides [15].
HIV-Exposed Seronegative (HESN)
It is appreciated that not everyone who is exposed to HIV
will necessarily become infected. Individuals demonstrating
natural resistance to HIV infection, referred to as HIV-
exposed seronegative (HESN), are considered to be a
model on which novel prevention efforts can be based. We
have followed a cohort of commercial sex workers (CSW)
from the Pumwani district of Nairobi, Kenya since 1984. A
proportion of CSW in the Pumwani cohort (~5-10%) have
been identified as HESN [16]. Several correlates ofprotection have been identified in various HESN cohorts,
but no single factor accounts for all cases of resistance to
infection. However, emerging evidence from studies of the
Pumwani cohort and others, implicates immune quies-
cence in protection against infection. Immune quiescence
refers to a state of low baseline immune activation, which
we propose protects against infection by limiting HIV
target cells and substrates available for HIV replication.
T cell immune quiescence
To evaluate the role of T cell activation on resistance to
infection, T cells were phenotyped in HESN and HIV-
negative, yet susceptible, CSW from the Pumwani cohort.
Reduced CD69+ CD4+ and CD8+ T cells were observed
in HESN when compared with controls, indicating low
levels of T cell activation [17].
Further evidence of low T cell activation in HESN partic-
ipants of the Pumwani cohort is provided by a study in
which microarray technology was implemented to investi-
gate CD4+ T cell function [18]. These analyses revealed
that unstimulated CD4+ T cells from HESN had a lower
level of gene expression than high risk HIV-negative
controls, suggesting a quiescent cellular state. A subse-
quent study confirmed these observations by examining
gene expression in whole blood [19]. Genes involved in T
cell receptor signaling and host factors required for HIV
replication were among the underexpressed genes in
HESN [18,19]. Unstimulated cells from HESN were also
found to secrete lower levels of cytokines ex vivo compared
to control groups, but this difference in cytokine secretion
was not observed following stimulation [18], indicating
that HESN have a low baseline level of cellular activation,
but respond normally to stimulation and are not immuno-
suppressed. Likewise, a recent study demonstrated reduced
production of proinflammatory cytokines and chemokines
by unstimulated lymphoctyes from HESN relative to
low-risk HIV-negative controls [20]. While the majority of
cytokines were comparable between groups following
stimulation of peripheral blood mononuclear cells (PBMC),
IL-17 and IL-22 remained lower in HESN compared to
controls, suggesting blunted TH17 responses in HESN
[20].
Evidence for T cell immune quiescence in HESN is not
limited to the Pumwani cohort. For instance, low
frequencies of CD4+ and CD8+ T cells expressing the
activation markers HLA-DR, CD38, CD70 and Ki67 were
identified in HESN men who have sex with men (MSM)
[21], and studies of serodiscordant couples found
reduced expression of CD38 [22], HLA DR and CCR5
[10] on CD4+ T cells from the uninfected partner.
Lymphocytes isolated from HESN CSW from a cohort in
Côte d’Ivoire expressed lower levels of CD69 and reduced
proinflammatory cytokines and chemokines following allos-
timulation compared to low-risk HIV-negative controls
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Republic and intravenous drug users in Vietnam showed
that despite higher CD8+ T cell activation, there were sig-
nificantly fewer CCR5+ CD4+ T cells in the blood of HESN
[10,24]. Also, independent studies of uninfected hemo-
philiacs who were exposed to HIV-contaminated blood
products [25] and of high-risk MSM [21] found reduced
lymphoproliferation in HESN compared to healthy con-
trols. Together, these studies from a variety of cohorts
showed a common phenotype of reduced systemic im-
mune activation in HESN.
Immune quiescence in the female genital tract
The majority of HIV transmissions occur at the genital
mucosa. As such, mucosal immunology is a central issue in
studies of HIV susceptibility. Evaluations of inflammation
in the female genital tract have demonstrated immune
quiescence at the mucosal level. For instance, cervical
mononuclear cells (CMC) from HESN from the Pumwani
cohort were shown to have reduced expression of genes
encoding proinflammatory cytokines compared to high-
risk HIV-negative CSW from the same cohort [20]. Of
note, reduced cervical expression of IL-17 and IL-22 were
observed in that study, consistent with observations from
the peripheral blood. TH17 cells expressing these cytokines
may be an important target for HIV infection, as these cells
are enriched in the CMC population and are preferentially
depleted in HIV-infected individuals [26].
CMCs from HESN from the Pumwani cohort were also
observed to have reduced expression of genes encoding
various pattern recognition receptors (PRRs), including
toll-like receptor (TLR)-2, TLR-4, TLR-7, TLR-8, RIG-I
and MDA5. HESN also had reduced expression of
UNC93B, which is involved in trafficking of TLRs
within the cell. CMCs also produced low basal levels of
cytokines in culture, but were highly responsive to stimu-
lation with the TLR7/8 ligand ssRNA40, suggesting that
despite low levels of PRRs at baseline, HESN are capable
of mounting an appropriate anti-viral response [27].
Consistent with reduced proinflammatory cytokine
expression by CMCs, reduced expression of IL-1α, IL-8,
MIG and IP-10 were found in HESN cervicovaginal lav-
age (CVL) samples compared to high-risk HIV-negative
controls [28]. MIG and IP-10 are both IFNγ-inducible
chemokines that bind the receptor CXCR3, inducing
recruitment of activated T cells. Lower levels of these
chemokines would result in a decreased recruitment of
activated T cells to the FGT. Consistent with this, a trend
toward reduced proportions of cervical HLA DR+CD8+ T
was observed in HESN [28].
Overall, these studies described HESN individuals with
lower levels of inflammation at the FGT that may result
in fewer HIV target cells at the point of first encounter
with HIV.Drivers of immune quiescence
Regulatory T cells (Tregs)
Due to the capacity of Tregs to suppress cellular activation,
the role of these cells in maintaining T cell quiescence was
investigated in HESN from the Pumwani cohort. Tregs
were found to be elevated in HESN relative to high-risk
HIV-negative controls [17].
Tregs suppress T cell activation and responses through
multiple mechanisms, both indirectly, through produc-
tion of anti-inflammatory cytokines or interactions with
dendritic cells (DC), and directly, though direct contact
with CD4+ and CD8+ T cells [29]. As such, elevated levels
of Tregs in HESN may protect against infection by limiting
activation of conventional CD4+ T cells. Although Tregs
are known to suppress antigen-specific T cell responses,
one study found that PBMC from HESN with elevated
Treg frequencies did not show enhancement of HIV-
specific T cell proliferation upon Treg depletion [30],
suggesting that HESN can maintain HIV-specific T cell
responses in the presence of Tregs.
Tregs may also protect against infection by additional
mechanisms. For example, Tregs can directly suppress
HIV replication through the activity of cyclic adenosine
monophosphate (cAMP), which negatively regulates
HIV replication [31,32].
Paradoxically, Tregs can be infected with HIV [33-35],
suggesting that elevated Tregs may actually provide
additional target cells for HIV infection. However, although
X4-tropic viruses preferentially target Tregs, these cells are
less susceptible to infection with R5-tropic HIV strains
than conventional CD4+ T cells [35]. Since mucosal HIV
transmission occurs in a CCR5-dependent manner [36],
Tregs may not be a major target cell during early transmis-
sion events. Furthermore, the Treg transcription factor
Foxp3 has been shown to repress HIV long terminal repeat
(LTR) transcription in infected cells [37,38], although one
study presented the disparate finding that Foxp3 enhanced
HIV LTR activity [39]. Therefore, elevated Treg levels may
drive lower levels of immune activation in HESN subjects.
Antiproteases
In addition to regulatory cell subsets, other potential
drivers of the immune quiescent phenotype include innate
proteins that play a role in the control of inflammation.
To identify putative factors involved in mediating resist-
ance against infection, a proteomics approach was applied
to screen for differences in CVL proteins between HESN
and high-risk HIV-negative CSW from the Pumwani
cohort. These comparisons revealed that HESN overex-
pressed several antiproteases, including members of the
serpin A family, cystatin B, Elafin and A2ML1 [40,41]. In
line with these observations, Elafin has been identified as
a correlate of protection in HESN [42]. These antipro-
teases have anti-inflammatory activity and their presence
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get cell availability. Antiproteases are usually induced in
the presence of inflammatory cytokines and chemokines.
However, in HESN, serpins remain high in the absence of
inflammation and correlations between serpins and proin-
flammatory factors are absent [28], suggesting that consti-
tutive expression of serpins may help to maintain low
inflammation in the FGT of HESN CSW.
Interferon regulatory factor-1 (IRF-1)
IRF-1 is a key transcriptional activator and repressor
involved in inducing expression of inflammatory genes in
response to IFN signaling. In addition, IRF-1 can activate
transcription of the HIV genome during early stages of
HIV infection [43]. In the Pumwani cohort, specific
polymorphisms in IRF1 were shown to result in reduced
IFNγ-stimulated IRF-1 protein expression and were associ-
ated with resistance to infection [44], but not altered dis-
ease progression [45], suggesting that the protective effect
is limited to early events in HIV infection. HESN individ-
uals who lacked the “protective” IRF-1 genotype were
shown to have reduced IRF-1 response potential as a conse-
quence of differential epigenetic regulation [46]. The kinet-
ics of the IRF-1 response to IFNγ stimulation in HESN was
transient and immediately silenced in HESN. This was in
contrast to HIV-susceptible individuals, who demonstrated
a sustained IRF-1 response. These data emphasize the
observation that immune quiescence is not equivalent to
immunosuppression, as HESN are able to mount robust
immune responses at the innate [46] and adaptive [18]
levels. However, these responses are regulated such that im-
mune activation is quickly resolved, restoring a quiescent
basal state.
Murine studies have demonstrated that IRF-1 negatively
regulates Treg development by repression of the Treg
transcription factor Foxp3 [47]. As mentioned above,
Tregs are elevated in HESN, but the causes of this expan-
sion are unknown. It is conceivable that reduced IRF-1
protein expression alleviates repression of Treg differenti-
ation in HESN, allowing for higher Treg levels to develop,
although further studies are needed to directly address the
interplay between IRF-1 and Tregs. Along these same
lines, the chemokines MIG and IP-10, which were shown
to be reduced in the cervical mucosa of HESN [28], are
upregulated by IFNγ stimulation, suggesting that reduced
expression of IRF-1 may contribute to reductions in
mucosal chemokines. Future studies should focus on clari-
fying the role of the IFNγ signaling pathway and IRF-1 in
mediating the immune quiescent phenotype in HESN.
Immune quiescence model of protection against HIV
infection
As described in the sections above, elevated levels of im-
mune activation are associated with increased risk of HIVinfection, and protection from infection correlates with
immune quiescence. This is marked by reduced T cell
activation, reduced gene transcription, reduced lympho-
proliferation, reduced peripheral and mucosal cytokine
and chemokine production, elevated Tregs, elevated
mucosal anti-proteases and reduced IRF-1 expression and
IFNγ-responsiveness. Previous HESN studies have
demonstrated HIV-specific T cell responses, both sys-
temically and mucosally [48]. Taken together, these ob-
servations can be used to frame a model of reduced
susceptibility to infection. In HIV-susceptible individ-
uals, HIV exposure leads to penetration of the mucosal
barrier and establishment of infection in a small focus
of CD4+ target cells. Inflammation resulting from
infection drives infiltration of activated target cells,
which fuel propagation of infection and dissemination
to lymphoid tissues. Once dissemination occurs, the
infection cannot be cleared (Figure 1A). In contrast, in
HESN, innate molecules in the FGT mucosa may limit
establishment of the initial focus of infection through
direct anti-viral activity and maintenance of mucosal
integrity. While it is likely that some viral particles
penetrate the epithelial barriers and gain access to target
cells in the submucosa, Tregs and antiproteases main-
tain low levels of T cell activation, leading to reduced
availability of activated CD4+ target cells. Consequently,
the target cell population is limited to resting T cells,
which do not effectively support viral replication.
Reduced expression of proinflammatory cytokines and
chemokines prevents infiltration of activated target
cells. As such, the focus of viral replication remains
small and unproductive in HESN, allowing innate or
adaptive cells, such as NK or HIV-specific CTL, oppor-
tunity to clear the low-level infection and prevent
dissemination (Figure 1B).
Support for immune quiescence from animal models
The immune quiescence model is supported by studies of
mucosal simian immunodeficiency virus (SIV) transmis-
sion in non-human primates (NHP). In acute infection of
rhesus macaques, a small founder population of infected
cells is established in the submucosa within the first few
days following viral challenge. This founder population is
comprised of mainly resting CD4+ T cells, as these cells
outnumber activated cells. Local expansion of the founder
population occurs through low-level viral replication in
resting cells. However, the infection is fuelled by an influx
of activated target cells in the inflammatory infiltrate
resulting from the innate response to SIV [49]. In this
way, SIV exploits the inflammatory immune response to
gain access to target cells for viral replication and dissem-
ination of infection. Interestingly, topical administration of
the anti-inflammatory compound glycerol monolaurate
blunts the inflammatory response, preventing infiltration
Figure 1 Immune Quiescence Model of protection from HIV
infection. (A) In HIV-susceptible individuals, infection is established
in resting and activated CD4+ target cells. Inflammation drives
infiltration of activated target cells, which fuel viral propagation and
dissemination of infection. (B) In HESN, elevated levels of Tregs maintain
low levels of T cell activation, leading to reduced availability of activated
CD4+ target cells. HIV establishes infection in resting T cells, which
support low levels of virus replication. Reduced expression of
proinflammatory cytokines and chemokines prevents infiltration of
activated target cells. Productive infection is therefore reduced in HESN,
allowing HIV-specific CTL sufficient opportunity to clear the low-level
infection and prevent dissemination.
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from SIV infection [50]. Furthermore, vaccination of
macaques with a tolerogenic vaccine prior to SIV exposure
resulted in development of CD8+ Tregs that suppressed
CD4+ T cell activation and prevented the establishment of
SIV infection [51].
In SIV-infected animals, SIV-specific CD8+ T cells are
detectable by the second week of infection. However,
infection is well established by this time, such that the ratio
of HIV-specific CD8+ T cells to infected target cells is too
low to prevent further viral replication and dissemination
[52]. Nonetheless, mucosal HIV-specific T cells present atthe time of inoculation have been shown to be protective
against simian-human immunodeficiency virus (SHIV)
challenge [53]. We propose that in HESN, mucosal HIV-
specific T cells, which have been previously identified in
HESN [54], are present early enough to clear the initial
focus of infection prior to expansion and dissemination.Contradictory evidence
Data that conflict with the immune quiescence hypothesis
appear in reports of elevated immune activation as a correl-
ate of protection in HESN. Elevated levels of T cell activa-
tion and cytokine production have been found in systemic
or mucosal samples from cohorts of HESN injection drug
users (IDU) [24,55,56] and uninfected partners of HIV +
patients [24,55-57]. However, in the Vietnamese HESN
IDU cohort [24], activation of the CD8+ and NK T cell
compartments occurred at the same time as reduced levels
of CD4+ CCR5+ T cell targets. This suggests the possibility
that in certain cohorts, CD4+ T cell quiescence can occur
concomitantly with activation of other immune cell subsets.
It is possible that other disparate findings may be recon-
ciled by differences in the site or intensity of HIV exposure,
presence of other immunogenic factors or differences in
assays used to characterize immune activation.Translation of IQ into novel prevention approaches
An important consideration is the translation of the
immune quiescence hypothesis into interventions that
prevent HIV infection. Our model suggests that inducing
immune quiescence at the site of HIV exposure will reduce
the number of activated target cells, thereby preventing
infection or limiting it to small foci of infected resting target
cells, which can be cleared by mucosal HIV-specific T cells
or innate mechanisms. A practical method of inducing
immune quiescence in the mucosa may be a microbicide
that incorporates anti-inflammatory mediators into the
formulation, perhaps in combination with antiretroviral
compounds that have shown moderate efficacy in recent
trials [14]. This approach has been suggested based on
results of functional studies performed in the wake of the
CAPRISA 004 trial [15]. Suitable compounds would be
drugs that are already approved by the FDA, have outstand-
ing safety records, have a demonstrated ability to reduce
excessive immune activation, and are affordable for those in
developing countries. There are a number of potential
candidate anti-inflammatory compounds, such as type I
interferon blockers [58], cyclooxygenase type 2 inhibitors
[59], statin inhibitors [60], chloroquine [61,62] and others,
that address some or all of these criteria. An advantage of
the approach of inducing the IQ phenotype is that it is
targeting the host immune system and not the virus,
thereby limiting any pressure on HIV to mutate to evade
the mechanism.
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strategy to reduce HIV transmission, caution needs to be
taken to ensure that the limitation of excessive mucosal T
cell activation does not result in the induction of an inabil-
ity to mount a mucosal immune response. Indeed, it may
seem counter-intuitive to try to limit excessive immune ac-
tivation on the one hand, while at the same time inducing
anti-viral immune responses with an HIV vaccine. How-
ever, these goals are not incongruent. Limiting HIV target
cells by inducing IQ in the FGT can be accomplished on its
own, independent of an HIV vaccine. Should this strategy
be used in conjunction with an HIV vaccine, it would be
important to activate and educate the immune system with
the vaccine first, prior to inducing IQ in the FGT. It is
important to recall that the induction of IQ is not equiva-
lent to the induction of anergy. As shown, individuals with
high levels of quiescent T cells are capable of responding to
recall antigen or mitogens [63]. Indeed, in the Pumwani
HESN cohort we observe a quiescent phenotype [63] and
HIV-specific immunity [64,65]. Therefore, HIV-specific
immunity in the context of decreased generalized T cell
immune quiescence is not only highly plausible, but it has
been observed. As such, candidate formulations designed
to induce IQ will need to be tested for the ability to reduce
immune activation and inflammation without interfering
with HIV-specific CD8+ T cell responses or innate antiviral
mechanisms such as NK cells.
Conclusions
There are multiple examples that show pre-existing im-
mune activation prior to HIV exposure is a risk factor for
HIV infection. Informed by the study of HESN cohorts, the
IQ model suggests that reduced immune activation may
provide protection against HIV infection by limiting the
pool of activated target CD4+ T cells susceptible to HIV in-
fection. Differences in Tregs, antiproteases and IRF-1 may
drive the IQ phenotype. Future studies should focus on
how to induce immune quiescence in combination with
other strategies such as microbicides and HIV vaccines.
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